Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) – Investment analysts at Leerink Partnrs decreased their Q3 2024 earnings per share (EPS) estimates for Bolt Biotherapeutics in a research report issued on Wednesday, August 14th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings per share of ($0.24) for the quarter, down from their prior forecast of ($0.18). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.34) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.42) EPS and FY2028 earnings at ($0.31) EPS.
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.08). The firm had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.19 million. Bolt Biotherapeutics had a negative return on equity of 51.74% and a negative net margin of 556.59%.
Read Our Latest Stock Report on BOLT
Bolt Biotherapeutics Stock Performance
Shares of BOLT opened at $0.69 on Friday. Bolt Biotherapeutics has a 1 year low of $0.65 and a 1 year high of $1.56. The company’s 50 day simple moving average is $0.73 and its 200 day simple moving average is $0.98. The company has a market capitalization of $26.46 million, a price-to-earnings ratio of -0.42 and a beta of 0.94. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.68 and a current ratio of 5.68.
Institutional Trading of Bolt Biotherapeutics
A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. bought a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned about 0.09% of Bolt Biotherapeutics at the end of the most recent quarter. 86.70% of the stock is currently owned by institutional investors and hedge funds.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
Further Reading
- Five stocks we like better than Bolt Biotherapeutics
- Conference Calls and Individual Investors
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What does consumer price index measure?
- MarketBeat Week in Review – 8/12 – 8/16
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.